Clinical Trial Update: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) [Phase 4]

View source ↗

Summary

Completed Phase 4 exploratory study of INC424 (nilotinib) in patients with primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential throm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• INC424 (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) | Phase 4 | Status: COMPLETED | Results posted: 2015-03-03